Arjun Goyal, M.D.

"“The detection of AFib significantly improved over the past two decades, primarily due to advancements in technology, changes in clinical practice and increased awareness,” the authors wrote. “Approximately a third of patients with AFib are asymptomatic, and enhanced detection over time may lead to increased lifetime risk of diagnosed AFib. Another possible reason is the global increase in life expectancy.” Meanwhile, AFib patients faced high lifetime risks of developing heart failure (41%) or experiencing a stroke (21%). The lifetime risk of an AFib patient suffering a myocardial infarction was 12%. “Our findings encourage greater attention to secondary prevention of heart failure after AFib, and in line with a recent report from the National Heart, Lung, and Blood Institute, relevant future initiatives include development of non-anticoagulant pharmacotherapies, effective implementation of weight loss and risk factor modification, and designing successful programs for cardiac rehabilitation. As AFib is a common arrhythmia, a lower incidence of complications may reduce the future economic costs in healthcare.”" MedTech Innovator American Heart Association Heart Rhythm Society American College of Cardiology #epeeps LSI

44

2 Comments

🚀 Attention Investors and Healthcare Leaders! 🚀 R3i are thrilled to celebrate StratifiCare™ Pte. Ltd.'s CEO, Anthony Chua, who just landed in Dallas, Texas, to accelerate the progress of two revolutionary personalized medicine diagnostics: 🌟 Stratifiden - The world's first severe dengue prognostic that reduces unnecessary hospitalization by 67%, easing the emotional and financial burden on families. 🌟 Stratifirey - The world's first liver cancer diagnostic that predicts patient response to Y90 RE treatment, allowing clinicians to make informed decisions and reduce the agonizing 3 to 6-month wait for results. StratifiCare's journey is a testament to perseverance and innovation. To develop these groundbreaking products, it secured $35M in non-dilutive capital and less than $1M in venture capital. Anthony Chua's unwavering determination teaches us the power of persistence and the impact of every step forward. A special thank you to David Jacobson for welcoming StratifiCare™ Pte. Ltd. into our Texas triangle and the SMU Cox School of Business community. 💡 Investors and hospital administrators, this is your chance to be part of a transformative journey in personalized medicine. Reach out and learn how you can support and benefit from these pioneering advancements. Together let's accelerate impact 💡 NUS Overseas Colleges National University of Singapore Singapore Economic Development Board (EDB) #HealthcareInnovation #PersonalizedMedicine #DengueDiagnostic #LiverCancerDiagnostic #StratifiCare #InvestmentOpportunities #HealthcareLeaders #MedicalBreakthroughs #Valuebasedcare Enterprise Singapore

25

Nephrolytics: Transforming Kidney Disease care with Vision and Determination “The real difference between success and failure in a corporation can very often be traced to the question of how well the organization brings out the great energies and talents of its people… I believe that any organization, in order to survive and achieve success, must have a sound set of beliefs on which it premises all its policies and actions.” - Thomas Watson Jr. “A Business and Its Beliefs,” At Nephrolytics, we embrace this wisdom wholeheartedly. Our core belief is centered around transforming healthcare from a system burdened by the volume of disease to one that truly values the health of people. This mission propels every aspect of our work, from product development to strategic partnerships, echoing Watson’s conviction. Our journey is akin to that of Dr. Ignaz Semmelweis in 1847, who faced immense challenges in shifting medical practices to save lives. Despite the success of his infection control procedures, Semmelweis’s ideas were met with resistance and significant challenges. Similarly, Nephrolytics is dedicated to a path that is not easy but is undeniably crucial. We address the urgent need for systemic change—reducing physician burnout through more efficient systems and better data integration, and preparing for an impending physician shortage, particularly in nephrology. Our AI-driven platform functions as an EMR-agnostic stand-alone workflow station for providers, designed not only to enhance the quality of care but also to reduce cognitive burden & operational costs. It supports healthcare professionals in their mission to deliver exceptional care without undue strain. As we continue our journey, we seek more individuals to join us—those who resonate with our vision. We offer our advisors, investors and strategic partners not just an investment opportunity but a chance to share in a vision that transcends monetary contributions. This collaboration is about a shared mission and collective effort. Thomas Watson Jr. wisely stated that the enduring success of a corporation relies not just on its ability to adapt technologies or strategies but “fundamentally on how it cultivates and utilizes the energies and talents of its people.” He believed in the strength of an organization rooted in clear and firm beliefs, guiding all actions and decisions. This philosophy highlights the importance of fostering a unified purpose that deeply connects with everyone involved, ensuring resilience and continued relevance through changes and challenges. That is what I believe we are harnessing at Nephrolytics. Together, we are not merely participants in healthcare reform but are actively driving its evolution. Tina Gill Adam Haid Naeem Rahim Ali Nadeem Mian Ali Tyler Cady Hasan Ayub Brian Mason Matthew Brooks Yasir Lashari Kartik Sharma 🙌🏾 #Healthcare

65

6 Comments

In Episode 3 of the "Brain Cancer Science Talk" series on #MissionGBM, we chat with John de Groot, MD (Division Chief of Neuro-Oncology, UCSF) about immunotherapies, the need for combination protocols, Focused Ultrasound, and necessary improvements to clinical trial design and Regulatory framework to advance the development of treatment options for #braincancer patients. #FUS #ImmunoOncology #GBM #Onward #Nof1onBehalfofAll

34

We're all aware that people are living longer but it's the QUALITY of life that is so important. It's good to see governments and agencies (see below from the FDA) are recognizing this and aligning with initiatives to advance the improvement of patients lives by bringing treatments to patients in their home. Companies like PHYSIDIA are how we can support better, more accessible care and better lives for patients TODAY while simultaneously addressing the strain on public healthcare systems. #thefutureisnow #bepartofthesolution

9

This will be a fascinating SynBioBeta talk - on how the combined tools of synthetic biology allowed Creyon Bio to build a successful drug in a few months 😳

13

The FDA greenlighted one of our portfolio companies to move a novel antidepressant drug to Phase 2a clinical trial! I am excited to share important positive news from Freedom Biosciences, a San Francisco-based clinical-stage biotech we have invested in via LongeVC back in 2023. The company has just announced FDA approval of investigational new drug (IND) application for their FREE001 Phase 2a program in patients with treatment-resistant depression (TRD). Freedom Bio plans to initiate its Phase 2a clinical trial in the first half of this year, which has the potential to address a critical unmet medical need in patients suffering from TRD. FREE001 is a ketamine-based combination therapy for the treatment of TRD, which builds on John Krystal work in Yale University. He showed that the combination may extend the antidepressant effects of ketamine from 2-7 days up to 2 to 3 weeks. Major depressive disorder (MDD) is a debilitating and chronic condition with limited effective treatment options, and Freedom Bio tries to tackle its specific case, treatment-resistant depression, when a person diagnosed with MDD does not respond adequately to a course of appropriate antidepressant medication within a certain time frame. MDD is one of the most common mental health disorders in the United States (US), with an estimated 21.0 million adults (8.3% of all adults) having at least 1 major depressive episode in 2020 (link to statistics in the comments). MDD also impacts physical health, worsens outcomes of other medical conditions, and, on average, results in a 10-year reduction in life expectancy. I am inspired by the achievements of Dina Burkitbayeva and Freedom Bio’s team in this truly challenging and notoriously hard area of drug discovery! Way to go, folks. #neuroscience #drugdiscovery #FDA

89

6 Comments

One key reason why healthcare technologies like AI, telemedicine, and software haven't structurally lowered costs or broadened access for the entire system after decades of experimentation (excluding pure financial engineering of payer contracts) is the limited reimagining of care delivery itself, with asynchronous telemedicine as a notable exception. In the same way that digitizing physical paper failed to exploit the capabilities of a new computing medium for word processing, hosting physician-patient conversations over video does not transform the actual delivery of care. In telemedicine, many of the inputs (e.g., clinician time) and therefore cost structures of in-person care persist, which is why we often see fee-for-service telemedicine companies struggle to achieve economies of scale (i.e., growing revenues non-linearly while growing costs linearly). Until we deconstruct the components of a medical appointment – from intake and triage, to chart review, history gathering, physical examination, diagnosis, treatment, and follow-up – we will continue to be underwhelmed by the disconnect between the transformative potential of these technologies and real-world patient/system impact. I’m optimistic that the emergence of reliable and performant medical AI agents will urge us to perform this deconstruction and redesign the fundamental building blocks of a “medical appointment.”

215

39 Comments

Activation Capital is seeking #startups to participate in their NEW Frontier BioHealth program. APPLY NOW! https://lnkd.in/dBiSQuNZ - ❗ Application Deadline: June 17, 2024 - 🏁 Program Kickoff: August 8, 2024 - 🎉 Program End: November 22, 2024 - 💻 Location: All virtual except for three in-person events. Travel costs will be covered! -💰 Investment: We do not invest and we do not take any equity. - 🔬 Startups transitioning #lifesciences innovations from research to commercialization, particularly those originating from academic or federal research labs, are highly encouraged to apply. - 🌟 Startups with a clear commercialization path, some initial funding (dilutive or non-dilutive), a full-time founder, licensing, optioning, or the ability to demonstrate control of their IP are highly encouraged to apply. More About the Program: -Website: https://lnkd.in/dBiSQuNZ -Apply Here: https://lnkd.in/dAFb_XpE -Meet with Jackie to learn more: https://lnkd.in/dF3-Ga3h #medicaldevice #pharma #biotech #diagnostic

39

2 Comments

Many companies find that navigating the complexities of fundraising can be daunting, but you don't have to do it alone. 📈 2024 Highlights: The number of biotech assets in phase 3 clinical trials has increased compared to 2023. 📊 Trend Over a Decade: Over the past ten years, the number of active biotech products in phase 3 trials has increased fourfold. 🏢 Current Landscape: More than 430 companies are currently funding these trials, reflecting an annual growth rate of 13.7% since 2012 🌟 This growth in late-stage trials is attracting more investment into the biotech sector. Investors are typically more confident in funding companies with advanced clinical assets, leading to potentially higher funding rounds and partnerships Whether you're an investor on the hunt for the next big opportunity or a company in need of funding, this group is here to link you with the right people: https://lnkd.in/ey4v9x3U

19

6 Comments

This article by the WSJ is critically important for public health officials and HealthTech entrepreneurs to internalize. We need multiple solutions for patients to move towards post GLP-1 usage. These solutions need to be easy to implement, non-disruptive to daily life and focused on caloric restriction , lifestyle change and muscle gain. Too many startups are still focused on GLP-1 prescription and delivery. Not enough people focused on the next stage of the weight management journey. As the Journal states, the benefits of the GLP-1 craze are only going to be successful long term if the transition off of them is successful. Otherwise, we risk unforeseen, long term consequences to a large group of patients stuck on GLP-1's with no healthy way to transition off. https://lnkd.in/dYBd3HaN Meghan FitzGerald James Stearns Dominic Perks John LaMattina Raju Kucherlapati

29

2 Comments

Advice from today's esteemed panel on accessing #healthcare #investment. "It's never too early to build your network with investors. Socialize your ideas to help sharpen your thesis. You can never underestimate the value of early feedback." Rami Hannoush, Ph.D. "Surround yourself with an advisory board that actually helps. They should be working on your behalf to help you access THEIR networks." Jennifer Friel Goldstein "Build your network early and pressure test your story with advisors." Nate Chang "Get to Silicon Valley early and often, and leverage programs like #ValleyReady that CELS - Canadian Entrepreneurs in Life Science offers because it can be game changing for your business." Cedric Bisson

42

7 Comments

As the discourse shifts from models to compound AI systems / agents, we need better AI benchmarks to evaluate multi-modal and multi-step task performance, especially in healthcare and life sciences. When we wrote the first paper demonstrating ChatGPT's performance on the USMLE, we chose the US Medical Licensing Exam as a benchmark for accessibility, speed, and ease. This benchmark was never intended to represent AI model performance on real-world clinical tasks. Today, I still see so many research teams and startups using benchmarks (like the USMLE) that are ill-fitted for assessing the true clinical or scientific performance and utility of the models they are developing for real-world contexts. Benchmark development may be seen as a "less sexy" area of research, but it is of paramount importance. Years after the rise of the transformer, we still lack adequate benchmarks for so many single-step tasks in biomedicine. With compound AI systems (i.e., architectures that integrate multiple AI models to perform complex tasks) emerging, we need new benchmarks for agentic behaviors. I'd argue that developing an agent with novel capabilities without at least proposing a companion benchmark (if an industry standard does not yet exist) may hinder the adoption of said agent, especially for high-stakes workflows. Designing more benchmarks that capture/simulate real-world clinical and scientific workflows will help us mitigate the major discrepancies observed between in silico and in vivo performance and better support safe + effective deployment of AI in biomedicine. There are already brilliant people focused here, and we need more. DMs are open if you're researching or working in this area of multi-step/multi-modal benchmarking in healthcare and life sciences! #healthcare #ai #artificialintelligence #generativeai

100

18 Comments

Some great advice in this interview — featuring Jeffry Weinhuff of Visionary Ventures — relevant to all sub-sectors of #medtech. My favorite line is “investment capital is not tuition.” 😂 But the best advice stems from the insight that good exits via IPO or M&A processes with multiple buyers competing for your company require that most medtech companies must prove their value via strong commercial metrics. And doing that takes a lot of time, expertise and money. Plan, hire and raise capital accordingly. At Vensana Capital, our investment process centers on a deep analysis of every aspect of getting a breakthrough medtech innovation to market, no matter what stage of development a company is at today. We like entrepreneurs who believe their innovation can be highly impactful to patients. We love the ones who want to leave no doubt. https://lnkd.in/eDsUqgn6

81

1 Comment

_What makes a good investment in healthcare? _ When is a good time to start thinking about the path to exit? _Where do we see the next #unicorn in #systemichealth? Experienced healthcare investor Dai Feng from CareCapital Group joins me and Jonathan Levine for our very first *video* episode of the #ThinkOralHealth #podcast. Take a listen.

17

1 Comment

What if we could generate novel protein therapeutics using new computational tools, without having to discover them through trial and error? That’s what we at Flagship Pioneering asked ourselves in founding Generate:Biomedicines. With new, computationally-derived medicines now advancing in the clinic, the answer is clear: we can revolutionize drug development.

62

Looking back at the past 30 years, I remember myself doing science about 55-60 hours a week, and then helping venture capitalists and biotech start-ups about 70-80 h/week. Usually unsatisfied, sometimes exhausted, but pleased overall. This overexciting workaholism was somehow interrupted last year. I had less work and a lot of mountaineering, - climbed about 5.5 Chomolungma attitudes during the year. It feels like I have reached the stage at which it is a time to start sharing experiences and understanding of the universe. This week, I started to share by publishing an analytic report at SeekigAlpha about TG Therapeutics. This small biotech company has developed a third-to-market anti-CD20 mAb for the treatment of multiple sclerosis (MS). Along with the company, this report briefly touches upon current treatments for MS, the competitive landscape of therapeutics, and the uncertainties surrounding the development of new BTK inhibitors. https://lnkd.in/drAFx9vt

10

It's been great to get a first-row seat to Transition Biomining's evolution! Sasha Milshteyn walked into our offices for a casual meet & greet back in 2023, with just a notebook. He walked out of the meeting with a key fob to our offices and access to our labs, launching a stealth-mode build that would become Transition Bioming. haha! Copper is an entrenched industry, highly concentrated, and with an undeniably strong demand pull for the energy transition. The industry has to think hard about how to cater to demand at a time when ore quality is declining and mixed diverse mineralogies at mines prevent existing approaches to tap the reserves economically. Check out how Transition Biomining can make a dent with an asset-light approach that brings out the best in each heap of copper. Got to roll up my sleeves and made my first cameo with this video! Hope you enjoy it. https://lnkd.in/d6bD_r95 #copper #energytransiton #cleantech #climatetech #vc #seriesseed

40

1 Comment

Investing in companies that fill needs for health systems is a growth opportunity for both delivery organizations and start ups. Some systems are jumping in on their own, while others are partnering with like minded systems or with established VC firms. While this is a relatively new trend for systems, health plans have been making similar bets for many years. The benefits of becoming a health system portfolio company can be significant. Data, access to beta populations and real world coaching can be extremely beneficial. Start ups get mentoring and systems have to ability to leverage outside resources to solve relevant business problems. I predict a booming business!

4